XVIVO — Xvivo Perfusion AB Share News
0.000.00%
- SEK6.49bn
- SEK6.30bn
- SEK812.17m
Brief: Xvivo Has Executed Agreements With US Hospitals
Brief: Xvivo Perfusion Q1 Adj. EBITDA Up At SEK 15.4 Mln
Brief: Xvivo Gains Regulatory Approval In China For Perfadex Plus
Brief: Xvivo Perfusion Q4 EBITDA Loss Narrows To SEK 0.1 Mln
Brief: XVIVO Kidney Assist Transport Receives 510(k) Clearance By FDA
Brief: Xvivo Signs Partnership Contract With Contatti In Brazil
Brief: Xvivo Q2 EBITDA Decreases TO SEK 5.3 Million
Brief: XVIVO Presents Strategic Focus Areas For 2022-2026
Brief: Xvivo Perfusion Q2 Net Loss Narrows To SEK 8.9 Mln
Brief: Xvivo Enters Partnership With University Medical Center Groningen
Brief: Xvivo Perfusion Q1 Adjusted EBITDA Up At SEK 6.3 Mln
Brief: Xvivo Perfusion Q4 EBIT Loss At SEK 14.3 Million
Brief: Xvivo Perfusion Q3 EBITDA Swings To Loss Of SEK 11.2 Million
Brief: XVIVO Perfusion To Buy Dutch Medtech Company Organ Assist
Brief: Xvivo Perfusion: XPS Sold To Lung Transplant Clinic In Europe
Brief: XVIVO Perfusion Appoints Dag Andersson President And CEO
Brief: Xvivo Perfusion Q1 EBITDA Up At SEK 7.6 Mln
Brief: Xvivo Perfusion: Xps™ Sold To Pediatric Transplantation Clinic In Italy
Brief: Xvivo Perfusion Updates On Covid-19 Effect On Xvivo Perfusion